[{“box”:0,”content”:”
Objectives: The B-cell lymphoma-2 (Bcl-2) is a protein that is particularly though to be involved in preventing apoptosis. Bcl-2 family members also essential for cancer survival, and its over expression has been linked to tumor genesis, development and resistance to anticancer treatments. The Bcl-2 family of members that inhibit apoptosis is a promising target for the creation of anticancer drugs. Methods: The study was based on computational approach using different phytocompounds for evaluating their potential against Bcl-2 protein. The compound namely epigallocatachin gallate and their similar compounds derived from Pubchem and three known inhibitor of Bcl-2 was selected. Molecular docking was conducted systematically using Pyrex and Biovia to determine the binding affinities between bioactive compounds. The pharmacological characteristics and toxicity of the compounds, analyzed by using Swiss ADME and ADMETlab 2.0. Results: The docking results revealed that some phytocompounds were the best inhibitor of Bcl2 protein, especially (2R,3R)-2-(3,4,5-trihydroxyphenyl) chroman-3-yl 3,4,5-trihydroxybenzoate. Perfectly binds inside the pocket of target protein like standard drug. The pharmacological studies also revealed that non toxicity and carcinogenicity. Conclusion: This computational study finding might help develop potential drug to combat standard drugs. The findings could aid in the creation of affordable, all-natural cancer treatments.
‘>nnnn[foreach 286][/foreach]nnnn<meta name=DC.Description xml:lang=en content='
Objectives: The B-cell lymphoma-2 (Bcl-2) is a protein that is particularly though to be involved in preventing apoptosis. Bcl-2 family members also essential for cancer survival, and its over expression has been linked to tumor genesis, development and resistance to anticancer treatments. The Bcl-2 family of members that inhibit apoptosis is a promising target for the creation of anticancer drugs. Methods: The study was based on computational approach using different phytocompounds for evaluating their potential against Bcl-2 protein. The compound namely epigallocatachin gallate and their similar compounds derived from Pubchem and three known inhibitor of Bcl-2 was selected. Molecular docking was conducted systematically using Pyrex and Biovia to determine the binding affinities between bioactive compounds. The pharmacological characteristics and toxicity of the compounds, analyzed by using Swiss ADME and ADMETlab 2.0. Results: The docking results revealed that some phytocompounds were the best inhibitor of Bcl2 protein, especially (2R,3R)-2-(3,4,5-trihydroxyphenyl) chroman-3-yl 3,4,5-trihydroxybenzoate. Perfectly binds inside the pocket of target protein like standard drug. The pharmacological studies also revealed that non toxicity and carcinogenicity. Conclusion: This computational study finding might help develop potential drug to combat standard drugs. The findings could aid in the creation of affordable, all-natural cancer treatments.
‘>nnnnnnnnnnnnnnn<meta property=og:description content='Request PDF |
Objectives: The B-cell lymphoma-2 (Bcl-2) is a protein that is particularly though to be involved in preventing apoptosis. Bcl-2 family members also essential for cancer survival, and its over expression has been linked to tumor genesis, development and resistance to anticancer treatments. The Bcl-2 family of members that inhibit apoptosis is a promising target for the creation of anticancer drugs. Methods: The study was based on computational approach using different phytocompounds for evaluating their potential against Bcl-2 protein. The compound namely epigallocatachin gallate and their similar compounds derived from Pubchem and three known inhibitor of Bcl-2 was selected. Molecular docking was conducted systematically using Pyrex and Biovia to determine the binding affinities between bioactive compounds. The pharmacological characteristics and toxicity of the compounds, analyzed by using Swiss ADME and ADMETlab 2.0. Results: The docking results revealed that some phytocompounds were the best inhibitor of Bcl2 protein, especially (2R,3R)-2-(3,4,5-trihydroxyphenyl) chroman-3-yl 3,4,5-trihydroxybenzoate. Perfectly binds inside the pocket of target protein like standard drug. The pharmacological studies also revealed that non toxicity and carcinogenicity. Conclusion: This computational study finding might help develop potential drug to combat standard drugs. The findings could aid in the creation of affordable, all-natural cancer treatments.
‘>nnnnnnnn
n
n
- [foreach 286]n
Balasundari A., Vitthalrao B. Khyade
n
n[/foreach]
n
- [foreach 286] [if 1175 not_equal=””]n
- Student,, Professor,Department of bioinformatics, Bionome, Department of Zoology, Sharadabai Pawar Mahila Arts, Commerce and Science College,,Bangluru, Shardanagar Tal., Baramati, Pune, Maharashtra,,India, India
n[/if 1175][/foreach]
n
n
n
Abstract
n
Objectives: The B-cell lymphoma-2 (Bcl-2) is a protein that is particularly though to be involved in preventing apoptosis. Bcl-2 family members also essential for cancer survival, and its over expression has been linked to tumor genesis, development and resistance to anticancer treatments. The Bcl-2 family of members that inhibit apoptosis is a promising target for the creation of anticancer drugs. Methods: The study was based on computational approach using different phytocompounds for evaluating their potential against Bcl-2 protein. The compound namely epigallocatachin gallate and their similar compounds derived from Pubchem and three known inhibitor of Bcl-2 was selected. Molecular docking was conducted systematically using Pyrex and Biovia to determine the binding affinities between bioactive compounds. The pharmacological characteristics and toxicity of the compounds, analyzed by using Swiss ADME and ADMETlab 2.0. Results: The docking results revealed that some phytocompounds were the best inhibitor of Bcl2 protein, especially (2R,3R)-2-(3,4,5-trihydroxyphenyl) chroman-3-yl 3,4,5-trihydroxybenzoate. Perfectly binds inside the pocket of target protein like standard drug. The pharmacological studies also revealed that non toxicity and carcinogenicity. Conclusion: This computational study finding might help develop potential drug to combat standard drugs. The findings could aid in the creation of affordable, all-natural cancer treatments.
n
Keywords: Bcell lymphoma 2, Epigallocatechin gallate, Venetoclax, Phytocompounds.
n[if 424 equals=”Regular Issue”][This article belongs to International Journal of Bioinformatics and Computational Biology(ijbcb)]
n
n
n
n
n
Full Text
n
n
n
n
n
n[if 379 not_equal=””]
Browse Figures
n
n
[/if 379]n
References
n[if 1104 equals=””]n
1. Clare M. Adams, Sean Clark-Garvey, PiperluigiPorus and Christine M. Eischem (2019). Targeting the Bcl-2 family in B Cell Lymphoma. Sec. Hematological Malignancies.
2. Shirin Hafezi and Mohamed Rahmani (2021). Targeting Bcl-2 in Cancer: Advances, Challenges and Perspectives.
3. Zhe Cheng, Zhifa Zhang, Yu Han, Jing Wang et.al (2020). A review on anti-cancer effects of green tea catechins. Journal of functional foods Volume 74.
4. Jiangyan Wang, Yu anXie, Yan Feng, Litu Zhang, Xinping Huang, Xiaoyun Shen, Xiaoling Luo (2015). (-)-Epigallocatechingallate induces apoptosis in B Lymphoma Cells via caspase-dependent pathway and Bcl-2 family protein modulation. International journal of oncology 46: 1507–1515, 2015.
5. Isha Kapoor, Juraj Bodo, Brian T. Hill, Eric D. His and AlexandruAlmasan (2020). Targeting Bcl-2 malignancies and overcoming therapeutic resistance. Cell Death and Disease (Nature publishing Group) – Volume. 11, Iss:11, pp 941.
6. Saleh A. Almatroodi, Ahmad Almatroudi, Amjad Ali Khan, Fahad A et.al (2020). Potential Therapeutic Targets of Epigallocatechingallate (EGCG), the Most Abundant Catechin in green tea, and its role in the therapy of various types of cancer. Molecules 2020,25,3146.
7. Andrew W Robets (2020). Therapeutic development and current uses of Bcl-2 inhibition.Hematogy Am Soc Hematol Educ Program DOI: 10.1182/hematology.2020000154.
8. Delphine Merino, Seong L Khaw, Stefan P Glaser et.al (2012). Bcl-2, Bcl-Xl and Bcl-W are not equilant targets of ABT-737 and Navitoclax(ABT-263) in lymphoid and leukemic cells. Blood 119(24): 5807–5816.
9. Terstappen GC and Reggiani A (2001). In silico research in drug discovery. Trends in pharmacological science, 22:23–26.
-
Guang-Jian Du, Zhiyu Zhang, Xiao-Dong Wen et.al (2012). Epigallocatechin gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients; 4(11:1679–91
11. A M Petros, A Medek, D G Nettesheim, D H Kim, H S Yoon, K Swift, E D Matayoshi, T Oltersdorf, S W Fesik (2001). Solution structure of the antiapoptotic protein Bcl-1. DOI: 10.1073/pnas.041619798.
12. Sophie Barille-Nion, Steven Lohard and Philippe P. Juin (2020). Targeting of Bcl-2 family members during anticancer treatment: A necessary compromise between individual cell and ecosystemic responses? Biomolecules 10(8): 1109.
13. SargisDallakyan, Arthur J Olson (2015). Small-molecule library screening by docking with PyRX. Methods of Mloecular Biology 2015;1263:243–50.
14. PradeepkrishnanJangampalli Adi, Nanda Kumar Yellapu, Bhaskar Matcha (2016). Modeling, Molecular docking,Probing catalytic binding mode of acetyl-COA malate synthase G Brucella melitensis 16M. BiochemBiophys Rep.2016;8:192–199.
15. Christopher A Lipinski (2004). Lead and drug-like compounds; the rule of five revolution. Drug Discovery Today Technologies, 1: 337–34
16. Xiaong G, Wu Z,Yi J, Fu L, Yang Z et.al (2021).ADMETlab 2.0: an integrated online platform for accurate and comprehensive prediction of ADMET properties. Nucleic Acid Reaserch 49 (W1).
17. Sager Yusuf, Adamu Uzairu, BalarabeSagagi, Muhd SabiuSuleiman (2019). In Silico molecular docking and pharmacokinetic study of selected phytochemicals with Estrogen and Progesterone receptor as anticancer agent for breast cancer. Journal of Turkish Chemical Society; 5(3):
1337–1350.
18. C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney (2001). Experimental and computational approaches to estimate solubility and permeability in drug and development settings. Advenced Drug Delivery Reviews; 46(1-3):3–26.
19. Ghulam Hussain, Usman Ali Ashfaq, Mahmood-ur-Rahman et.al (2019). Computational screening of phytochemicals against surviving protein: A potent target for cancer. Pakistan journal of pharmaceutical science: 1145–1154.
20. SenbagaraniRenganathan, Sunil Kumar Sahu and Kandasamy Kathiresan (2015). Phytochemical and molecular docking analysis of Prosopis juliflora derived phytochemicals against anti-apoptotic protein Bcl-2. World journal of Pharmaceutical Research volume 4.
21. Fisayo A Olotu, Clement Agoni, Emmanuel Adeniji, Maryam Abdullahi, Mahmoud E Soliman (2019). Probing Gallate-Mediated Selectivity and high-affinity binding of Epigallocatechin Gallate: a way-forward in the design of selective inhibitors for Anti-apoptotic Bcl-2 proteins. Appl BiochemBiotechnol 187(3): 1061–1080.
22. SiddavaramNagini, Ramesh Nivetha, Manikandan Palrasu, Rajakishore Mishra (2021). Nimbolide, a neem Limonoid, is a promising candidates for the anticancer arsenal. Journal of Medicinal Chemistry 64(7):3560–3577.
n[/if 1104][if 1104 not_equal=””]n
- [foreach 1102]n t
- [if 1106 equals=””], [/if 1106][if 1106 not_equal=””],[/if 1106]
n[/foreach]
n[/if 1104]
n
n[if 1114 equals=”Yes”]n
n[/if 1114]
n
n
n
International Journal of Bioinformatics and Computational Biology
n
n
n
n
n
n
Volume | 01 |
Issue | 02 |
Received | March 2, 2023 |
Accepted | April 15, 2023 |
Published | April 30, 2023 |
n
n
n
n
n
n[/foreach]
n
n
n
[/foreach]
n
nEditnn function myfun() {n x=document.getElementById(“editor”);n y=document.getElementById(“down”);n z=document.getElementById(“up”);n if(x.style.display==”none”){n x.style.display=”block”;n }n else {n x.style.display=”none”;n }n if(y.style.display==”none”){n y.style.display=”block”;n }n else {n y.style.display=”none”;n }n if(z.style.display==”none”){n z.style.display=”block”;n }n else {n z.style.display=”none”;n }n }n function myfun2() {n x=document.getElementById(“reviewer”);n y=document.getElementById(“down2”);n z=document.getElementById(“up2″);n if(x.style.display==”none”){n x.style.display=”block”;n }n else {n x.style.display=”none”;n }n if(y.style.display==”none”){n y.style.display=”block”;n }n else {n y.style.display=”none”;n }n if(z.style.display==”none”){n z.style.display=”block”;n }n else {n z.style.display=”none”;n }n }n
n
n
nn function myFunction2() {n var x = document.getElementById(“browsefigure”);n if (x.style.display === “block”) {n x.style.display = “none”;}n else {x.style.display = “Block”;}}n document.querySelector(“.prevBtn”).addEventListener(“click”, () => {n changeSlides(-1);});n document.querySelector(“.nextBtn”).addEventListener(“click”, () => {n changeSlides(1);});n var slideIndex = 1;n showSlides(slideIndex);n function changeSlides(n) {n showSlides((slideIndex += n));}n function currentSlide(n) {n showSlides((slideIndex = n));}n function showSlides(n) {n var i;n var slides = document.getElementsByClassName(“Slide”);n var dots = document.getElementsByClassName(“Navdot”);n if (n > slides.length) {slideIndex = 1;}n if (n (item.style.display = “none”));n Array.from(dots).forEach(n item => (item.className = item.className.replace(” selected”, “”))n );n slides[slideIndex – 1].style.display = “block”;n dots[slideIndex – 1].className += ” selected”;n }n
“}]